Skip to main content

Table 1 Patient clinical characteristics (n = 75)

From: Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

 

n

%

Age (years)

 Median (range)

65 (40–80)

Sex

 Male

49

65

 Female

26

35

Stage grouping*

 I

12

16

 II

5

7

 III

31

41

 IV

27

36

Histology

 Adenocarcinoma

56

75

 Squamous cell carcinoma

18

24

 Pleomorphic carcinoma

1

1

EGFR status#

 Mutation not found

47

63

 Mutation found

28

37

ALK/ROS1 status†

 Rearrangement not found

72

96

 Rearrangement found

3

4

  1. Abbreviations: EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase; ROS1 = c-ros oncogene 1
  2. * Staging was performed according to the guidelines of the American Joint Committee on Cancer, 8th edition
  3. # EGFR mutation was defined as the presence of an EGFR exon19del or L858R mutation in tumor genomic DNA
  4. † ALK/ROS1 rearrangement was defined as the presence of an ALK or ROS1 rearrangement in tumor genomic DNA
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us